- 21Jan, 2026
A conversation with Ajit Parhi, Ph.D., chief scientific officer, TAXIS Pharmaceuticals Antimicrobial resistance (AMR) poses a grave threat to global public health and is estimated to cause around 10 million deaths each year by 2050if not addressed. While U.S. government prioritization of AMR is likely [...]
How Innovation is Turning the Tide in the Costly Fight Against Antimicrobial Resistance
A century ago, antibiotics transformed medicine. What were once deadly infections suddenly became curable, ushering in an era where surgery, childbirth, and even everyday cuts carried far less risk. Unfortunately, that medical miracle is now under threat. Across the world, doctors and healthcare systems are [...]
Smart Investing in Antimicrobial Resistance Solutions Disrupts Biotech Market
Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.
Hospital-Acquired Pneumonia: Rethinking Treatment in the Face of Antibiotic Resistance
Hospital-acquired pneumonia (HAP) stands as one of the most significant challenges in patient care, representing a leading cause of morbidity among hospitalized patients. This formidable infection not only contributes to extended hospital stays but also leads to increased healthcare costs and a greater burden on healthcare systems. Companies like TAXIS Pharmaceuticals have the potential to transform outcomes for patients battling this condition.
- 24Jul, 2025
As we navigate the complexities of modern medicine, a quiet threat remains: multi-drug resistant gonorrhea (MDRSG, commonly referred to as Super Gonorrhea), a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae. Super gonorrhea is a prime example of how bacteria can outsmart our best defenses. At TAXIS, we are diving headfirst into the science of combating antimicrobial AMR.
- 27Jul, 2025
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.
- 15Jul, 2025
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
